Question 1

Is SS-31 peptide safe?

Accepted Answer

A single word cannot carry the answer, and the record for this compound shows why: what exists is a set of trials in people who were already ill, each observed for a fixed period, together with one regulatory decision about one inherited disease. The decision came in 2025. A review of that year's approvals records that elamipretide became the first disease-specific treatment approved for Barth syndrome. An approval is a regulatory judgment that benefit outweighs harm for one defined group of patients, and it is not a statement about anybody outside that group. A 2026 review in Sports Medicine discusses SS-31 (elamipretide) alongside other peptides that people take for recovery and performance. Its verdict on the unapproved members of that list is that rigorous human safety data are scarce, and there is potential for serious harm to patients. So the honest answer has two halves: in one diagnosed disease a regulator has weighed the evidence, and for every other purpose the evidence is a handful of trials in patients rather than a measured safety profile.

Question 2

What side effects did the Barth syndrome extension record?

Accepted Answer

This is the longest human exposure on record, and harm was its principal question. In the TAZPOWER extension, the primary endpoints were safety and tolerability, which means the study was built to watch for problems first and for benefit second. The most frequent problem was local, with the authors reporting injection-site reactions being the most common adverse events, which is consistent with a route that involved injecting under the skin every day for more than three years. Then consider the numbers. Ten patients entered the OLE; 8 reached the week 168 visit. The published summary does not explain why two participants did not finish, and that omission matters on a page about harm. The authors concluded that elamipretide was associated with sustained long-term tolerability and efficacy. Read that as what it is, a judgment drawn from eight people with the same rare disease who all knew what they were receiving, which makes it a genuine observation rather than a frequency anybody could apply to themselves.

Question 3

What did the 218-person Phase 3 record about harm?

Accepted Answer

This is the stronger design, because it included a comparison group. In MMPOWER-3, participants (N = 218) were randomized (n = 109 elamipretide; n = 109 placebo), and each group injected for 24 weeks without knowing which assignment it had received. The safety finding fits in a single line, since the trial reported most adverse events being mild to moderate in severity. That is a statement about how severe the events were, rather than about how many occurred or which ones they were, and the published summary stops at that point. A placebo arm is what makes a safety record interpretable, because some events in any long trial originate from the disease, the season or chance, and only a group given a dummy injection reveals how much of that background exists. The summary does not set the two arms side by side for harm, so a reader learns the severity and not the difference. The trial itself is now listed on the public registry as TERMINATED, and the registry entry does not say that harm was the reason.

Question 4

Is SS-31 safe for the heart?

Accepted Answer

The heart is where much of the human work was done, and that cuts both ways. Barth syndrome, the one approved use, is itself a heart disease. A clinical reference states that in patients with it, heart failure is a significant cause of morbidity and mortality; risk of arrhythmia and sudden death is increased. So the patients who received elamipretide longest had weakened hearts to begin with, rather than healthy ones, which complicates any reading of cardiac harm in either direction. Heart failure trials followed. One registered study looked at the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure, and it is listed as completed with no result among these sources. A smaller study gave it after a heart attack, where 10 of the patients received the mitochondria-targeting peptide elamipretide. Reviews of heart failure research are hopeful and careful at once. One 2018 review describes this group of approaches as working without causing the adverse neurohormonal side effects associated with current guideline-based therapies. A 2022 review says the newer approaches, elamipretide among them, have been leading to mixed results. Neither is a cardiac safety profile for a healthy heart, which none of these trials enrolled.

Question 5

Is it safe to take SS-31 at night?

Accepted Answer

No study among the research behind this page compared different times of day, so there is no finding to report for evening against morning administration; what the trials specified was the amount, the route and the frequency, rather than the hour. In the Barth syndrome work, patients entering the extension continued elamipretide 40 mg subcutaneous daily. In the larger muscle disease trial the instruction was 24 weeks of elamipretide at a dose of 40 mg/d or placebo subcutaneously. Once daily is the only timing information either published summary provides. Sleep was not a measured outcome in any of these trials either. A question about night use is therefore really two questions, whether timing changes anything and whether it disturbs sleep, and neither has been asked of this compound, which is different from a finding that timing does not matter. The amounts themselves, and why none of them is a protocol, are set out on the SS-31 dosage page.

Question 6

Does SS-31 affect blood sugar?

Accepted Answer

Nobody has measured blood sugar in a person given SS-31 in any study covered here, and the wider family of compounds aimed at mitochondria has a mixed record on it. A 2024 editorial reports that efforts to target mitochondria for glycemic control in diabetes using mitochondria-targeted antioxidants have produced inconsistent results. Glycemic control means keeping blood sugar in range. The one direct measurement is in animals. In aged female mice made fat-livered on a high-fat, high-fructose diet, the authors report that the compounds tested also improved insulin sensitivity by increasing p-Akt and GLUT2 expression in those mice. Insulin sensitivity is how well the body responds to its own insulin. So the animal signal points away from harm, and the human question has not been asked. For someone using insulin or a glucose-lowering medicine, the gap is the important part. A mouse result in a diet model does not tell anybody what happens when SS-31 is added to those medicines in a person, because no trial among these sources has tried it.

Question 7

Is SS-31 hard on the liver or kidneys?

Accepted Answer

Every organ result on record comes from animals or cells, and all of them point toward protection rather than damage. That is worth knowing, and it is not the same thing as an organ safety study in people. For the kidney, a 2023 mouse paper recalls that earlier long-term dosing had improved cardiovascular diastolic function, and glomerular architecture of the kidney in aged mice, the glomeruli being the kidney's filters. Its own lighter schedule did not affect kidney function as previously reported using continuous treatment. In pig kidney cells kept in a dish, mitoprotection improved mitochondrial structure and function as well as the capacity of MetS + RAS STCs to repair injured tubular cells in vitro. For the liver, the 2026 experiment in fat-livered mice found that both MitoQ and SS-31 significantly improved mitochondrial protein expression and overall liver health compared with untreated MASLD mice. None of the human trials here published liver or kidney readings in their summaries, so the organ question in people has been measured only by whatever routine blood tests the trials ran and did not report.

Question 8

Who was left out of the SS-31 trials?

Accepted Answer

Most people who might consider it, because every completed trial enrolled a named diagnosis and each diagnosis brought its own narrow population. The largest trial took participants with genetically confirmed PMM, meaning primary mitochondrial myopathy confirmed by a gene test. Its group had an average age of 45.6 years (64% women; 94% White), so the record says little about other ancestries. The approved population is narrower still. The clinical reference describes Barth syndrome as a multisystem disorder characterized in affected males by cardiomyopathy, neutropenia, skeletal myopathy, and prepubertal growth delay. That makes the longest safety record almost entirely male. Healthy adults are the clearest gap. A Study of Healthy Aging and Physical Function With Elamipretide is listed as RECRUITING, and it has published nothing. None of the summaries reports a harm figure for pregnancy or for children as a separate group. Being left out of a trial is not the same as being harmed, but it does mean the record is silent rather than reassuring.

Question 9

What does SS-31 interact with?

Accepted Answer

No interaction study in people appears among the research behind this page, so there is no list of medicines to avoid and no list of safe pairings either. What exists is laboratory work on combinations, and it answers a narrower question than the one a reader is asking. In skin cells taken from people with Friedreich ataxia, an inherited nerve disease, researchers paired SS-31 with a second peptide. They found that the combination of TAT-P110 and SS-31 does not affect FRDA patient fibroblasts differently from SS-31 alone. Fibroblasts are the cells that build connective tissue. The same paper notes that SS-31 changed the shape of mitochondria but it does not affect ATP levels, ATP being the cell's energy currency. That is a cell dish, rather than a body taking several medicines at once. The Barth syndrome reference lists standard heart failure medications among the usual care for that disease, yet the trial summaries do not say which medicines participants were taking, or whether any combination behaved differently. Stacking SS-31 with other peptides is a separate question again, and it has not been studied in the sources covered here.

Question 10

How long does the human safety record run?

Accepted Answer

It extends further than for most compounds on this site, and it becomes thinner the further out it goes: at 24 weeks there are roughly 109 people who received elamipretide in a placebo-controlled trial, and at 168 weeks there are eight. The earliest trials were shorter still, and a 2022 review summarises them by stating that in early-phase clinical trials, elamipretide administration has not resulted in any severe adverse events. Early-phase trials are deliberately small and brief, so this is a statement about the first examination rather than the long view. The same review is plain about where that leaves things, calling for additional studies to describe the long-term safety and efficacy of elamipretide. That sentence was written before the approval, and the approval rests on the Barth syndrome extension rather than on any new long-term study. So the long-term record remains eight people with one disease. Rare harms, the kind that appear once in a thousand users, cannot surface in a group that small, which is a limitation of size rather than evidence of absence.

Question 11

Does the FDA approval cover a vial sold as SS-31?

Accepted Answer

No. The approval is a regulatory fact about one product, one disease and one outcome. The clinical reference words it exactly: elamipretide is indicated for the improvement of muscle strength in individuals with Barth syndrome. A 2026 review of the year's approvals records that in 2025, the FDA approved 46 novel drugs, including four TIDEs (one peptide among them, and that peptide is elamipretide. What the regulator assessed was the approved product, made to a known standard and given at a known amount to a known group. A vial labelled SS-31 and bought outside that approval has not been through any of this. The 2026 Sports Medicine review draws the line between peptides that passed a rigorous approval process that evaluates both safety and efficacy and those that did not. The molecule may share a name, but the approval belongs to the approved product rather than to the name, and nothing on the label of an unapproved vial carries it across.

Question 12

Is SS-31 banned in sport?

Accepted Answer

None of the sources behind this page states where SS-31 sits on an anti-doping list, so this page will not assert a status either way. That is a gap in what we can cite, rather than evidence that it is permitted. What the sources do show is that sports medicine is paying attention to it. The 2026 Sports Medicine review covers prominent approved and unapproved peptides marketed direct to patients, and it names SS-31 among them. Its stated aim is to help clinicians navigate patient discussions about peptides with athletes who ask about them. An approval for Barth syndrome does not settle the sporting question, because anti-doping rules are written by sporting bodies rather than by drug regulators. The current prohibited list of the relevant governing body is the only document that settles the matter for a competitor.

Question 13

Why is the SS-31 harm record still this thin?

Accepted Answer

Because the trials that would have built it were small, short or stopped. That is the pattern across mitochondrial medicine, rather than something peculiar to this compound. A 2017 review of the field describes agents of this kind being used based on limited number of clinical trials, and lists elamipretide as a cardiolipin protector (elamipretide). A heart failure review from the same year concludes that large randomised controlled trials are required to confirm the role of metabolic-modulating drugs. A 2025 editorial on mitochondria in heart failure still frames its task as setting out the key challenges that must be addressed to translate these innovations into clinical practice. The disease behind the approval is rare, so its trials could only ever be small, while the larger trial ran 24 weeks and is now listed as terminated. A harm record accumulates when many people take something for a long time under observation, and that has happened here only in miniature. The benefits measured in those same trials are weighed on the SS-31 benefits page.

SS-31 side effects and safety data